Supplementary Figure 1



Supplementary Figure 1: Analysis of monocyte subsets and lineage relationships. (**a**) Gating strategy for definition of MDP and cMoP populations in BM of *Cx3cr1*$^{GFP/+}$ mice related to **Fig. 1a**. MDP was defined as CD11c^{-}MHC-II^{-} cells from live CD45^{+}Lin^{-}CD11b^{-}CD117^{+}CD115^{+}GFP^{+} population. For cMoP Ly6C^{+}CD11c^{-}MHC-II^{-} subset was gated from live CD45^{+}Lin^{-}CD11b^{-}CD117^{+}CD115^{+}GFP^{+} population. (Lin: CD3, CD45R/B220, CD19, NK1.1, Ly6G, CD49b). (**b**) Gating strategy for identification of monocyte and GC (top) or MDP and cMoP (bottom) subpopulations in wild-type (*Cx3cr1*$^{+/+}$) mice.

Supplementary Figure 2



Supplementary Figure 2: Validation of gating strategy in *Nr4a1-GFP* mice and adoptive transfer experiments. (**a**) Flow cytometry plot depicting validation of CX_3CR1 based gating strategy (corresponding to gating in *Cx3cr1*$^{GFP/+}$ mice, in **Fig. 1a**) precisely identifies Nr4a1-GFP^{+}CD43^{+}Ly6C$^{lo/-}$ monocytes in bone marrow. (**b**) Flow cytometry plot depicting validation of CX_3CR1 independent gating strategy (corresponding to gating in wild type mice, in **Supplementary Fig 1b**) precisely defines Nr4a1-GFP^{+}CD43^{+}Ly6C$^{lo/-}$ monocytes.

Supplementary Figure 3



Supplementary Figure 3: Ly6C^{hi} monocyte adoptive transfer experiments. (**a**) Sorting strategy for adoptive transfer of CD11b^{+}GFP^{+}Ly6C^{hi} monocytes. (**b**) Schematic illustration of adoptive transfer and multicolor flow cytometry analysis of Ly6C^{hi} monocytes from GFP^{+}CD45.2^{+} mice into CD45.1^{+} recipients. (**c**) 4th and 5th rows of flow cytometry plots from **Fig. 1d** are shown. Donor CD45.2^{+}CD11b^{+}GFP^{+} cells are black. For comparison CD45.1^{+}CD11b^{+}Ly6C$^{lo/-}$F4/80^{lo} recipient monocytes are depicted in blue (representative of two experiments).

Supplementary Figure 4



Supplementary Figure 4: Specificity and efficiency of *Cre* expression and *Notch2* targeting. (**a**) Flow cytometry plot showing gradual expression of *LysM-eGFP* in myeloid cell subpopulations from cMoP to Ly6C^{lo} monocytes. (**b**) Flow cytometry plot showing YFP expression in bone marrow of *LysM^{Cre}Rosa^{YFP}* or control *Rosa^{YFP}* mice. *LysM^{Cre}* is strongly active in monocytes (Ly6C^{hi} and Ly6C^{lo}) and granulocytes but not in other cell populations. (**c**) Quantitative RT-PCR in sorted bone marrow cells from *GFP^{+}Notch2$^{\Delta My}$* mice showing highest expression of *Cre* in N2^{-}Ly6C^{hi} and subsequent reduction in Ly6C^{lo} monocytes (n=6). * P<0.05, ** P<0.01, *** P<0.001; 1way ANOVA with Bonferroni's multiple comparison test. Error bars represent s.e.m. (**d**) Notch2 expression in Ly6C^{hi} and Ly6C^{lo} monocyte subpopulations isolated from BM of *Notch2$^{\Delta CD11c}$* mice (representative of two experiments). Littermate controls are shown for comparison.

Supplementary Figure 5



Supplementary Figure 5: Myeloid cell populations in *Notch2* deficient mice. (**a**) Monocyte subpopulation analysis based on CD115^{+} gating strategy reveals reduction of Ly6C^{lo} but not Ly6C^{hi} monocytes in *GFP^{+}Notch2$^{\Delta My}$* mice. Data are pooled from three experiments (n=8/11). (**b**) Absolute or relative numbers of granulocytes in *GFP^{+}Notch2$^{\Delta My}$* mice. Data are pooled from three experiments (n=8/10). (**c**) Relative frequency of monocytes by flow cytometry in *Notch2$^{\Delta My}$* with wild-type *Cx3cr1* locus. Data are pooled from three experiments (n=9/11). (**d**) Myeloid cell populations in *LysM^{Cre}Notch2$^{+/+}$* and *LysM$^{+/+}$Notch2$^{+/+}$* littermate control mice. Data are from three experiments (n=7/8). (**e**) Myeloid cell population analysis in *N1$^{\Delta My}$* mice (n=8/9). Data are pooled from three experiments. (**f**) Myeloid cell population analysis in *N1N2$^{\Delta My}$* mice. Data are pooled from two experiments (n=5/6). (**a-f**) * P<0.05, ** P<0.01, *** P<0.001; Student's t test. Error bars represent s.e.m.

Supplementary Figure 6



Supplementary Figure 6: Notch2 deficient BM Ly6C^{hi} monocytes show impaired conversion potential *in vivo*. (**a, b**) Flow cytometry (**a**) and corresponding fluorescence minus one controls (FMO ctrls) (**b**) 4 days after adoptive transfer of Ly6C^{hi} monocytes (corresponding to **Fig. 4c**) from control or Notch2 deficient CD45.2^{+}GFP^{+} donors into CD45.1^{+} congenic recipients. (**a**) Transferred cells are shown in black and for comparison, recipient CD45.1^{+} (1st row), CD45.1^{+}CD11b^{+} (2nd row), CD45.1^{+}CD11b^{+}Ly6C^{hi} (3rd row) cells or CD45.1^{+}CD11b^{+}Ly6C^{hi}F4/80^{lo} monocytes (4th and 5th rows) are depicted in blue.

Supplementary Figure 7



Supplementary Figure 7: Notch2 deficient peripheral Ly6C^{hi} monocytes show impaired conversion potential *in vivo*. (**a**) Flow cytometry plots 4 days after adoptive transfer of pooled splenic and peripheral blood Ly6C^{hi} monocytes from control or Notch2 deficient CD45.2^{+}GFP^{+} donors into CD45.1^{+} congenic recipients. Transferred cells are shown in black and for comparison, recipient CD45.1^{+} (1st row), CD45.1^{+}CD11b^{+} (2nd row), CD45.1^{+}CD11b^{+}Ly6C^{hi} (3rd row) cells or CD45.1^{+}CD11b^{+}Ly6C^{hi}F4/80^{lo} monocytes (4th to 5th rows) are depicted in blue (representative of two experiments).

Supplementary Figure 8



Supplementary Figure 8: Notch ligand DLL1 mediates monocyte conversion *in vitro*. (**a**) Gating strategy for definition and quantification of Ly6C^{lo} monocyte-like cells *in vitro*. Ly6C^{lo} monocyte-like cells (CD11b^{+}GFP^{+}Ly6C$^{lo/-}$CD11c^{lo}CD43^{+}MHC-II$^{lo/-}$) are calculated as a percentage of live CD11b^{+}GFP^{+} cells. (**b**) Flow cytometry plot showing expression of CD115 and upregulation of GFP on *in vitro* converted Ly6C^{lo} monocyte-like cells. *Ex vivo* isolated GFP^{+}Ly6C^{hi} BM monocytes served as a staining control.

Supplementary Figure 9



Supplementary Figure 9: ***In vivo*** **targeting of endothelial cells in mice.** b(**c**) Specific β-galactosidase activity in capillaries and large vessels of peripheral muscle (top) and in aortic EC (en face preparations (bottom)) after treatment of *lacZ*^{iEC} or control mice with tamoxifen; scale bar 100µm. Image is a representative of two (muscle) or three (aorta) experiments. (**d**) PCR for floxed or recombined locus of *Dll1* from heart (left), lung (middle) and peripheral muscle (right). Results are from one experiment representative of 4 experiments. (**e**) Quantitative RT-PCR analysis of *Dll1* expression in sorted ECs from control or *Dll1*$^{i\Delta EC}$ mice. Pooled from three experiments (n=3). (**f**) Myeloid cell population analysis in *Dll1*$^{+/+}$ or *CreERT2 Dll1*$^{+/+}$ mice after tamoxifen treatment showing no influence of tamoxifen on Ly6C^{lo} monocyte development. Data are pooled from two experiments (n=6/7). (**g**) Cell population analysis in *Cdh5(PAC)-CreERT2 Dll1*$^{f/f}$ mice showing no influence of *Cdh5(PAC)-CreERT2* expression on Ly6C^{lo} monocyte development. Data are pooled from three experiments (n=6/8). (**e-g**) * P<0.05, ** P<0.01, *** P<0.001; Student's t test. Error bars represent s.e.m.

Supplementary Figure 10



Supplementary Figure 10: *In vivo* targeting of arterial endothelial cells in mice. (**a**) β-galactosidase staining demonstrates specific staining in central arteries of splenic follicles, arteries of peripheral muscle and aorta in *lacZ*^{iaEC} mice. Scale bars 100µm. Results are from one experiment representative of two independent experiments. (**b**) PCR for floxed or recombined *Dll1* locus (*ΔDll1*) from aortas (n=2).

Supplementary Table 1: Surface phenotype signatures for identification of distinct myeloid populations *in vivo*

Population	Phenotype
MDP	$Lin^-CD117^+CD11b^-CD115^+CX_3CR1^+Ly6C^-F4/80^-CD11c^-MHC\text{-}II^-$ or $Lin^-CD117^+CD11b^-CD115^+Ly6C^-F4/80^-CD11c^-MHC\text{-}II^-$
cMoP	$Lin^-CD117^+CD11b^-CD115^+CX_3CR1^+Ly6C^{hi}F4/80^-CD11c^-MHC\text{-}II^-$ or $Lin^-CD117^+CD11b^-CD115^+Ly6C^{hi}F4/80^-CD11c^-MHC\text{-}II^-$
$Ly6C^{hi}$	$Lin^-CD117^-CD11b^+CX_3CR1^{lo}Ly6C^{hi}F4/80^{lo/-}CD11c^-MHC\text{-}II^{lo/-}CD43^-$ or $Lin^-CD117^-CD11b^+Ly6C^{hi}F4/80^{lo/-}CD11c^-MHC\text{-}II^{lo/-}CD43^-$
$Ly6C^{lo}$	$Lin^-CD117^-CD11b^+CX_3CR1^{hi}Ly6C^{lo/-}F4/80^{lo}CD11c^{lo}MHC\text{-}II^{lo/-}CD43^+$ or $Lin^-CD117^-CD11b^+Ly6C^{lo/-}F4/80^{lo}CD11c^{lo}MHC\text{-}II^{lo/-}CD43^+$
GC	$Lin^+CD11b^+CX_3CR1^-Ly6C^{lo}$ or $Lin^+CD11b^+Ly6C^{lo}$
Atypical cells ($Ly6C^{lo}$)	$Lin^-CD117^-CD11b^+CX_3CR1^{hi}Ly6C^{lo/-}F4/80^{lo}CD11c^-MHC\text{-}II^{hi}CD43^-$ or $Lin^-CD117^-CD11b^+Ly6C^{lo/-}F4/80^{lo}CD11c^-MHC\text{-}II^{hi}CD43^-$

Lin: CD3, CD45R/B220, CD19, NK1.1, Ly6G, CD49b

Supplementary Table 2: Mouse models used in the study

Abbreviations	Mouse description	Mouse background
CD45.1^{+}	B6.SJL-*Ptprc^{a}Pepc^{b}*/BoyJ	*B6*
GFP^{+} ctrl *GFP^{+} N2$^{\Delta My}$*	*LysM$^{+/+}$ Notch2$^{lox/lox}$ Cx3cr1$^{GFP/+}$* *LysM^{Cre} Notch2$^{lox/lox}$ Cx3cr1$^{GFP/+}$*	B6 *B6*
Ctrl *N2$^{\Delta My}$*	*LysM$^{+/+}$ Notch2$^{lox/lox}$* *LysM^{Cre} Notch2$^{lox/lox}$*	*B6* *B6*
Ctrl *N1$^{\Delta My}$*	*LysM$^{+/+}$ Notch1$^{lox/lox}$* *LysM^{Cre} Notch1$^{lox/lox}$*	*B6* *B6*
Ctrl *N1N2$^{\Delta My}$*	*LysM$^{+/+}$ Notch1$^{lox/lox}$ Notch2$^{lox/lox}$* *LysM^{Cre} Notch1$^{lox/lox}$ Notch2$^{lox/lox}$*	*B6* *B6*
wt *Dll1$^{+/lacZ}$*	*Dll1$^{+/+}$* *Dll1$^{+/lacZ}$*	*129* *129*
Ctrl *lacZ^{iEC}* *lacZ^{iaEC}*	*Gt(ROSA)26Sor* *Cdh5(PAC)-CreERT2 Gt(ROSA)26Sor* *Bmx(PAC)-CreERT2 Gt(ROSA)26Sor*	*B6* *B6* *B6*
Ctrl *Dll1$^{i\Delta EC}$* *Dll1$^{i\Delta aEC}$*	*Dll1$^{lox/lox}$* *Cdh5(PAC)-CreERT2 Dll1$^{lox/lox}$* *Bmx(PAC)-CreERT2 Dll1$^{lox/lox}$*	*Mixed, B6;129* *Mixed, B6;129* *Mixed, B6;129*
Ctrl *Dll4$^{i\Delta EC}$*	*Dll4$^{lox/lox}$* *Cdh5(PAC)-CreERT2 Dll4$^{lox/lox}$*	*Mixed, B6;CD1* *Mixed, B6;CD1*
Dll1$^{+/+}$ *CreERT2 Dll1$^{+/+}$*	*Dll1$^{+/+}$* *Cdh5(PAC)-CreERT2 Dll1$^{+/+}$*	*Mixed, B6;129* *Mixed, B6;129*
Ctrl *LysM^{Cre}*	*LysM$^{+/+}$ Notch2$^{+/+}$* *LysM^{Cre} Notch2$^{+/+}$*	*B6* *B6*
Nr4a1-GFP	*Nr4a1-EGFP/Cre*	*B6*
LysM-eGFP	*LysM-EGFP*	*B6*
Rosa^{YFP} *LysM^{Cre};Rosa^{YFP}*	*LysM$^{+/+}$ Gt(ROSA)YFP26Sor* *LysM^{Cre} Gt(ROSA)YFP26Sor*	*B6* *B6*
GFP^{+} ctrl *GFP^{+} N1N2$^{\Delta CD11c}$*	*CD11c^{Cre} Notch1$^{lox/+}$ Notch2$^{lox/+}$ Cx3cr1$^{GFP/+}$* *CD11c^{Cre} Notch1$^{lox/lox}$ Notch2$^{lox/lox}$ Cx3cr1$^{GFP/+}$*	*B6* *B6*
Ctrl *N2$^{\Delta CD11c}$*	*CD11c$^{+/+}$ Notch2$^{lox/lox}$* *CD11c^{Cre} Notch2$^{lox/lox}$*	*B6* *B6*

Supplementary Table 3: Antibodies and fluorescence dyes for flow cytometry and immunofluorescence used in the study

Antibody/dye	Clone	Dilution	Company
Anti-CD3ε	145-2C11	1:100	BioLegend
Anti-CD49b	DX5	1:400	BioLegend
Anti-CD45R/B220	RA3-6B2	1:400	BioLegend
Anti-Ly6G	1A8	1:400	BioLegend
Anti-CD19	1D3	1:400	BD Pharmingen
Anti-NK1.1	PK136	1:400	BioLegend
Anti-CD117	2B8	1:100	BioLegend
Anti-CD115	AFS98	1:100	BioLegend
Anti-CD11b	M1/70	1:400	BioLegend
Anti-Ly6C	HK1.4	1:2800	BioLegend
Anti-F4/80	BM8	1:100	BioLegend
Anti-CD11c	N418	1:400	BioLegend
Anti-I-A/I-E	M5/114.15.2	1:400	BioLegend
Anti-CD43	S7	1:400	BD Pharmingen
Anti-CD45	30-F11	1:200	BioLegend
Anti-CD45.1	A20	1:100	BioLegend
Anti-CD45.2	104	1:200	BioLegend
Anti-CD144	11D4.1	1:100	BD Pharmingen
Anti-CX_3CR1	SA011F11	1:200	BioLegend
Anti-CD11a	M17/4	1:200	BioLegend
Anti-CCR2	475301	1:100	R&D
Anti-Notch2	HMN2-35	1:100	BioLegend
Anti-CD16/CD32	93	1:200	BioLegend
Anti-CD31	Mec13.3	1:400	BD Pharmingen
Streptavidin PE-Dazzle594		1:400	BioLegend
Annexin V		1:50	BioLegend
7AAD		1:100	BioLegend
Propidium Iodide		1:12000	Sigma
Anti-GFP		1:300	Acris
Anti-DLL1	HMD1-3	1:100	BioLegend
Streptavidin Cy3		1:400	BioLegend
Anti-rabbit IgG-FITC		1:200	Jackson ImmunoResearch
DAPI		1:5000	Invitrogen

Supplementary Table 4: Primers for QRT-PCR

Gene	Primers
Notch2	Forward: AGTGTCAGAGGCCAGCAAGAAGAA Reverse: TGATTGTCGTCCATCAGAGCACCA
Notch1	Forward: TGGAGGTCTCAGTGGCTATAA Reverse: ATTCTGGCATGGGTTAGAAAGA
Hey2	Forward: TGAAGCGCCCTTGTGAGGAA Reverse: TTGTAGCGTGCCCAGGGTAA
Hes1	Forward: CCGGACAAACCAAAGACGGC Reverse: GGAATGCCGGGAGCTATCTTTCT
Dll1	Forward: TCCGATTCCCCTTCGGCTTC Reverse: TGGGTTTTCTGTTGCGAGGT
Nr4a1	Forward: AGCTTGGGTGTTGATGTTCC Reverse: AATGCGATTCTGCAGCTCTT
Pparg	Forward: AGGGCGATCTTGACAGGAA Reverse: CACCTCTTTGCTCTGCTCCT
Pou2f2	Forward: TGCACATGGAGAAGGAAGTG Reverse: AGCTTGGGACAATGGTAAGG
Slfn5	Forward: AGGTCGAACGATTCTGCTGT Reverse: TCTGAGGGAAACTGGAAAGG
Ccr2	Forward: CCTTGGGAATGAGTAACTGTGTGAT Reverse: ATGGAGAGATACCTTCGGAACTTCT
Cx3cr1	Forward: GCAGAAGTTCCCTTCCCATC Reverse: GGACAGGAAGATGGTTCCAA